Proteomic identification and validation of novel biomarkers for monitoring the early phase of renal transplantation

被诊断为肾衰竭的人数正在增加。当肾脏完全衰竭时，最严重的治疗方法是透析或肾脏移植。移植与更好的生活质量、更大的存活率和更便宜有关，每年为NHS节省超过4.9亿英镑。然而，移植的肾脏并不总是立即起作用，或者它们可能会被排斥。发现问题最常见的方法是测量血液中某种物质（肌酐）的水平，然后从肾脏组织中取一小块（活检），但这有风险，对患者来说是不愉快的，而且当损害已经太大时，可能做得太晚了。这个项目旨在寻找更好的生物标志物，即可以在血液或尿液样本中测量的物质（蛋白质），并为我们提供有关肾脏是否正常工作的早期信息，如果不是，帮助我们快速确定哪里出了问题。这将使我们能够以最好的方式治疗患者，并在短期和长期内防止移植肾脏的损失或功能障碍。

The number of people being diagnosed with kidney failure is increasing. The treatments for the most severe forms when the kidneys fail completely are dialysis or a kidney transplant. Transplantation is associated with a better quality of life, greater survival, and is cheaper, saving the NHS more than £490 million per year. However, transplanted kidneys don‘t always work immediately, or they may be rejected. The most common way of finding out that there is a problem is by measuring levels of a substance (creatinine) in the blood and then taking a small piece (biopsy) of the kidney tissue but this has risks, is unpleasant for the patient and may be done too late when too much damage has happened. This project is aimed at finding better biomarkers, that is substances (proteins) which can be measured in a blood or urine sample and give us earlier information about whether the kidney is working properly, and if it isn‘t, help us decide quickly what is going wrong. This would enable us to treat the patient in the best way and prevent loss or misfunctioning of the transplanted kidney, both in the short and longer term.